VTCN1 and neoplasm: Notably, a recent study by Yuan et al., demonstrates that B7x, an immune-checkpoint ligand expressed by tumor cells, suppresses anti-tumor immunity in pNETs and as such, could be an attractive target for (p)NET immunotherapy [78].